About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
 
  About Us
  Research & Development
  Biopharmaceuticals
  Branded Formulations
  Financial Results
  - Transcript of Q1FY'16
  - Investor Presentation
  - Annual Reports
  Facilities Virtual Tour
  Downloads
  - Biocon Profile
  - CMD Profile
  - Video Gallery

          Patient Contact

          Patient Contact

for more details, please visit:
www.bioconacademy.com

Write to:
admissions@bioconacademy.com



     
 

At Biocon, we are driven by our passion to develop research - driven cutting edge therapies. Our tryst with innovation has enabled us to address the relatively unmet needs of our patients through differentiated products in challenging therapeutic spaces. We have earned the trust of patients and doctors through our products that are safe, efficacious and affordable. We are constantly engaged in pursuit of excellence to find solutions that heal the world.

Biocon is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise we serve our customers and partners in over 85 countries. We are committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer.

Through innovative products and research services we are constantly enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. We have successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'.
Some of our key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody.

We have a rich pipeline of biosimilars and novel biologics at various stages of development including a high potential oral insulin.


As the largest Indian Insulins Company, we believe we have made a huge difference to millions of diabetic patients in India. Over the years Biocon has also emerged as a leading Indian oncology company making cancer-care 'affordable' and 'accessible' to patients in India.

read more...


 
   
   
   
 

 

 

Highlights of Q1 FY'16 Results




Stock Update
 
 
 

  Latest Press Release
 

Aug 11, 2015:
Syngene Intl lists at Rs 295 on BSE; NSE; closes at a premium of 24% at Rs 310.55 on Listing day

 
  Media Coverage
 

Aug 17, 2015
Economic Times:
With Syngene Valuation, She is a ShehanShaw...

July 24, 2015
Financial Express:
Biocon posts 23% rise in net profit at Rs 126 cr in Q1

 
 

Biocon Foundation


Arogya Raksha Yojana


Biocon Malaysia

     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer | Authorised Users               © 2015, Biocon. All Rights Reserved